Evaxion Biotech (EVAX) has announced promising results from its Phase 1 dose-escalation study of EVX-01, its leading personalized cancer vaccine candidate for metastatic melanoma. The findings revealed that 67% of patients (8 out of 12) exhibited objective clinical responses—six partial responses and two complete responses. Notably, the administration of EVX-01, in conjunction with anti-PD1 therapy, did not result in serious adverse events attributable to the vaccine.
"We are encouraged by the data from our ongoing Phase 2 study of EVX-01, which were presented at this year's annual ASCO meeting. We remain on track to report our one-year readout in the third quarter of this year," stated Christian Kanstrup, CEO of Evaxion.
For more health news, visit rttnews.com.
